- Investor Overview
- Stock Information
- News Releases
- Events & Presentations
- SEC Filings
- STOCKHOLDER MEETINGS
AND PROXY MATERIALS
- Corporate Governance
- Contact Jaguar IR
|View printer-friendly version|
|Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board|
From 2006 to 2013, Dr. Chaturvedi served as Napo's Chief Scientific
Officer and has remained a scientific adviser to the company since 2014.
His track record of successful development includes participating in
and/or leading development efforts for seven drugs, including Napo’s
Mytesi® (crofelemer) product, which is approved by the U.S.
Napo recently convened a
Mytesi® is also being explored for treatment of important orphan gastrointestinal indications such as congenital diarrheal disorders (CDD) and diarrhea associated with short-bowel syndrome (SBS). CDDs are a group of rare, chronic intestinal channel diseases characterized by large, watery stools containing an excess of chloride and sodium, lifelong diarrhea, and a lifelong need for nutritional intake with a feeding tube. CDDs are related to specific genetic defects inherited as autosomal recessive traits, and the incidence of CCDs is much more prevalent in regions where consanguineous marriage is part of the culture.
Patients with SBS are born with a substantial shortening of the small
intestine, to a mean length of 50 cm, compared with a normal length at
birth of 190-280 cm. This could be due to either a genetic disorder or
pre-mature birth. In regions such as the
“With the early and extreme morbidity and mortality suffered by CDD and
SBS patients, we welcome the opportunity to participate in the
investigation of a novel drug to address the devastating diarrhea and
dehydration caused by these lifelong diseases for which there is
currently no available treatment except parenteral nutrition, and help
limit the suffering of patients and their family members,” stated Dr.
Mohamad Miqdady, Chief of Pediatric Gastroenterology, Hepatology &
Nutrition at Sheikh Khalifa Medical City in
Dr. Chaturvedi is also providing oversight for development of Napo’s
proprietary second-generation anti-secretory agent for cholera—a
possible indication that may present Napo with an opportunity for an
“I am thrilled to be supporting Napo’s and Jaguar’s shared mission to
change the global standard of care for gastrointestinal diseases,”
stated Dr. Chaturvedi. “I look forward to evaluating potential multiple
follow-on gastrointestinal indications for Mytesi®, and
leveraging the collective expertise of our team in advancing drug
development through innovative approaches such as the adaptive clinical
trial design that led to the
“We are very pleased that Dr. Chaturvedi has returned to support these principal development activities,” Conte commented, “which, if approved, will complement our current sales of Mytesi® for noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. We consider Mytesi® a ‘pipeline within a product’, and Napo has global unencumbered rights to this novel first-in-class anti-secretory agent with multiple potential follow-on indications.”
Dr. Chaturvedi has co-founded and led multiple biotech enterprises
including Scion, IndUS and Oceanyx, and has served as the CEO or CSO for
Scion, IndUS, Napo, and Oceanyx and is the CEO for
The proposed merger of Jaguar and Napo remains subject to customary
conditions to closing. Upon the consummation of the merger, Jaguar’s
name will be changed to
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
For more information, please visit www.napopharma.com.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the development, approval and sales of potential follow-on indications of Mytesi®, the proposed merger between Jaguar and Napo, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
|Print Page | Email Page | RSS Feeds | Email Alerts | Financial Tear Sheet|